Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity

Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity

IntroductionBNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.MethodsThis cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at b...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ho Yu Ng, Yunshi Liao, Ching Lung Cheung, Ruiqi Zhang, Kwok Hung Chan, Wai-Kay Seto, Wai K. Leung, Ivan F. N. Hung, Tommy T. Y. Lam, Ka Shing Cheung
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	gut microbiota vaccine COVID-19 vaccine vaccine immunogenicity BNT162b2 (Pfizer-BioNTech)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534787/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

COVID-19 vaccination-related attendance at a pediatric emergency department in Singapore among 12- to 18-year old adolescents
by: Nicholas Beng Hui Ng, et al.
Published: (2022-11-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Papuloerythroderma of Ofuji Associated with Elevated Varicella-zoster Virus Complement-fixing Antibody Titers Following BNT162b2 mRNA COVID-19 Vaccination
by: Masahiro Oka
Published: (2025-04-01)

BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
by: Chen-Wei Yen, et al.
Published: (2023-11-01)

COVID-19 Vaccination Protects Skeletal Muscle Against Statin-Related Side Effects
by: Daria Schetz, et al.
Published: (2025-03-01)

Eventos adversos por la vacuna COVID-19 Pfizer-BioNTech® en niños de 5-17años
by: María del Rocío Hernández-Morales, et al.
Published: (2024-12-01)

COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis
by: Angel Justiz-Vaillant, et al.
Published: (2025-01-01)

Löfgren’s Syndrome Following BNT162b2 mRNA COVID-19 Vaccination and Subsequent Plaque-type Cutaneous Sarcoidosis after its Resolution
by: Masahiro Oka, et al.
Published: (2025-06-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
by: Claudio Ucciferri, et al.
Published: (2022-02-01)

Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
by: Masliyana Husin, et al.
Published: (2025-01-01)

Letter to the Editor Regarding "Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination" by Albertson et al. 2024
by: Ivan Pourmir, et al.
Published: (2025-04-01)

Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platformResearch in context
by: Jennifer L. Nguyen, et al.
Published: (2025-01-01)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution
by: Andreina Baj, et al.
Published: (2021-01-01)

Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions
by: Ayako Konishi, et al.
Published: (2025-12-01)

A Systematic Review of Vascular Injuries: A Review of Petechiae, Purpura, and Ecchymosis in Critical Situations Following COVID‐19 Vaccination
by: Yasamin Kalantari, et al.
Published: (2025-03-01)

Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review
by: Eleonora Francesca Pattonieri, et al.
Published: (2025-02-01)

Effect of recent SARS-CoV-2 infection on anti-spike protein immunoglobulin G II response after BNT162b2 vaccination
by: Daiki Tanno, et al.
Published: (2025-08-01)

Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain
by: Luis Sarabia de Ardanaz, et al.
Published: (2025-05-01)

Side effects of the Pfizer BioNTech vaccine in health workers of a hospital in the southeast of Mexico
by: Jesús Arturo Ruiz-Quiñones, et al.
Published: (2022-09-01)

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial
by: Oyeniyi Diya, et al.
Published: (2025-07-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”
by: Timothy E. Albertson, et al.
Published: (2025-04-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant
by: Valentin Letailleur, et al.
Published: (2024-12-01)

Pre-Vaccination Immune Profiles and Responsiveness to Innate Stimuli Predict Reactogenicity and Antibody Magnitude Following mRNA Vaccination
by: Amanda E. Zelkoski, et al.
Published: (2025-07-01)

Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar
by: Remy Thomas, et al.
Published: (2025-03-01)

Safety and efficacy of RNA vaccines: State of the art
by: A. V. Blagov, et al.
Published: (2021-11-01)

Characteristics and outcomes of adverse events after COVID‐19 vaccination
by: Tariq Kewan, et al.
Published: (2021-10-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Allergy to PEG (polyethylene glycol) – sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024-12-01)

COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study
by: Asaf Shemer, et al.
Published: (2025-02-01)

Estimating the Effectiveness of Pfizer and Sinopharm Vaccines and their Relationship to Occupation, Residence, Smoking, and Body Mass Index During Pregnancy Smoking
by: Shahad Th. Jameel, et al.
Published: (2025-01-01)

Breakthrough Infection After a Primary Series of COVID-19 Vaccination Induces Stronger Humoral Immunity and Equivalent Cellular Immunity to the Spike Protein Compared with Booster Shots
by: Yoshifumi Uwamino, et al.
Published: (2025-07-01)

SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
by: Weiyi Tang, et al.
Published: (2025-03-01)

Immune Imprinting, Non-Durable Hybrid Immunity, and Hybrid Immune Damping Following SARS-CoV-2 Primary Vaccination with BNT162b2 and Boosting with mRNA-1273
by: Alejo Erice, et al.
Published: (2025-03-01)

Evaluating the Side Effects of COVID-19 Vaccines Available in Al-Diwaniyah Province
by: Meraim Attyah Kazaal, et al.
Published: (2024-09-01)

Nuclear Factor Erythroid 2-Related Factor 2 and SARS-CoV-2 Infection Risk in COVID-19-Vaccinated Hospital Nurses
by: Stefano Rizza, et al.
Published: (2025-07-01)